Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIP-3α-gp100-TRP2 DNA vaccine
- Development stage
- Preclinical
- Lead developer
- Johns Hopkins Bloomberg School of Public Health
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
The MIP-3α-gp100-TRP2 DNA vaccine is an experimental, preclinical-stage therapeutic cancer DNA vaccine developed by researchers at the Johns Hopkins Bloomberg School of Public Health. The vaccine construct consists of a pCMVe mammalian expression plasmid encoding the chemokine MIP-3α (also known as CCL20) genetically fused to two melanoma-associated antigens: gp100 (amino acids 25–235 of the human melanoma antigen) and Tyrosinase-Related Protein 2 (TRP2). Its mechanism of action involves targeting the CCR6 receptor on immature dendritic cells via the MIP-3α component, which directs the fused tumor antigens to these professional antigen-presenting cells to enhance the adaptive immune response against melanoma. In preclinical studies using the B16F10 mouse model, the vaccine is typically administered via intramuscular electroporation and has shown enhanced efficacy when combined with CpG adjuvants, type-I interferon, and epigenetic modulators like 5-Aza-2'-deoxycytidine to overcome immunosuppressive mechanisms in the tumor microenvironment.
- Other names
- MIP3α-gp100-TRP2 vaccineMIP-3α-antigen DNA vaccineMIP3α-antigen vaccineCCL20-gp100-TRP2 DNA vaccineCCL-20-gp100-TRP2 DNA vaccineCCL 20-gp100-TRP2 DNA vaccine
02
Targets
CCR6 (C-C motif chemokine receptor 6)PMEL (Melanocyte Protein PMEL)TYRP2 (Tyrosinase-related Protein 2)
Beyond the preview
Go deeper on MIP-3α-gp100-TRP2 DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIP-3α-gp100-TRP2 DNA vaccine.